The PD‐1/PD‐L1 pathway plays a leading role in tumor escape from immune responses.1 Immune checkpoint inhibitors abolish the inhibitory signal of T cell activation, allowing tumor‐reactive T cells to overcome regulatory mechanisms and produce potent antitumor responses.2, 3, 4 Pembrolizumab, an inhibitor of PD‐1/PD‐L1, was first approved for therapeutic use in 2014 and is currently available for treating various tumor types.5 Among them, non‐small cell lung cancer is the strongest indication for this therapy. This evidence concerns the gene CD274 and neoplasm.